Advertisement / Advertisement
This report that has now been published allows for various conclusions, which could be very beneficial for a disproportionate price development of InnoCan Pharma* (WKN: A2PSPW) today.
I wouldn't be surprised if it surpassed the CAD 1.00 mark (EUR 0.70)!
INNOCAN ANNOUNCES THE EXECUTION OF A RESEARCH & LICENSE AGREEMENT WITH RAMOT, THE TECHNOLOGY TRANSFER COMPANY OF THE TEL AVIV UNIVERSITY FOR CANNABINOIDS LOADED EXOSOME DELIVERY PLATFORM (CLX)
InnoCan Pharma* (WKN: A2PSPW) is pleased to announce today that - after the positive results of the CBD Loaded Exosome Platform (CLX) - has signed a new research and license agreement with Ramot. Ramot is the technology transfer company of Tel Aviv University (TAU). The new agreement extends the Research and Options Agreement between InnoCan Israel and Ramot dated April 17, 2020.
CLX (Cannabinoids Loaded Exosome) may have the potential to provide highly synergistic effects on tissues, such as regeneration and anti-inflammatory properties, targeting recovery of infected lung cells and central nervous system (CNS) disorders, among others. Exosomes have shown promise as nanocarriers for drug delivery and targeted therapy. Exosomes can act as "guided missiles" so to speak, targeting specific damaged organs. Exosomes can be loaded with therapeutic ingredients to increase their potential.
The new agreement expands on the original agreement by introducing a broader research work plan to be conducted over the next 21 months that will continue development of the CLX platform and expand the potential applications of the technology currently being developed. InnoCan Pharma* (NYSE:INNOCAN) will fund the cost of the work plan totaling $1,177,200, payable in four separate installments.
NEWS CONCLUSION:
I could imagine that the public only knows the tip of the iceberg of the findings from the CLX research. But now, with the signing of the contract with Ramot, the technology transfer company of Tel Aviv University, one has secured oneself legally and can inform the investors about the research results, provided the patent situation allows it. The first concrete areas of application were again defined today in the report that has now been published.
InnoCan Pharma* (NYSE:InnoCan) would once again be pumping significant funds into CLX research if initial trials did not suggest that a therapeutic effect could ultimately be achieved, that one would be able to to develop a treatment method that (to my knowledge) would be the first of its kind.
t.me/bullvestor
Prof. Chezy Barenholz, who conducts liposome/CBD research for InnoCan Pharma* (NYSE:INNOCAN) gave an interview. Prof. Barenholz is NOT on the board of InnoCan, he is a scientific advisor to the company and, together with his employees, conducts the LPT research in which CBD should have a higher and more controlled bioavailability in the organism with the help of liposomes. Barenholz developed Doxil®, a liposome-based cancer drug for which Johnson & Johnson paid $7 billion. An interview with him:
In summary, based on the information from the interview, the following can be said: For the first time, three different areas of application were shown and clinical pictures were also specifically named:
Barenholz mentions the low toxicity of CBD and thus also of the drug as a clear advantage of CBD. Also, an initial use should be easy to find, but gaining approval with that gives your foot in the door to review the drug for many other uses. Two different formulations are currently used for two different applications.
THESE ARE THE LAST PROMISING LIPOSOME/CBD PLATFORM RESULTS: INNOCAN PHARMA'S ANNOUNCES THE SUCCESSFUL DEMONSTRATION OF PROLONGED RELEASE OF CBD IN DOGS USING ITS LPT TECHNOLOGY
InnoCan Pharma* (NYSE:INNOCAN) announces that in his recent study in dogs, CBD administered using LPT (CBD-loaded liposome) technology shows prolonged plasma concentrations for at least six weeks after a single subcutaneous injection. These results are a significant advance in the development of technology that are good predictors of LPT behavior in humans.
The dog received a single subcutaneously injected dose of 5 mg/kg. The canine CBD plasma profile is shown in Figure 1. Importantly, the usual practice of oral CBD doses in the range of 1-4 mg/kg daily (given in two doses) has a half-life of 4-5 hours. This equates to administration of 30-120mg/kg per month compared to a single 5mg/kg dose of LPT lasting at least 6 weeks. These results open the door to a variety of exciting therapeutic possibilities.
Fig. 1: Pharmacokinetic (PK) profile of one of the dogs followed six weeks after an injection
NEWS CONCLUSION:
"This unique liposome platform technology can have a wide range of applications such as epilepsy, pain relief, inflammation or even diseases of the central nervous system and was filed for patent on October 7, 2019." - This is how the possibilities are also described in the press release!
The reason why these results are even more valuable than those from the experiments with mice lies in the greater similarity of the dog's organism in relation to humans.
The fact that my aunt's shepherd dog was prescribed the same anti-rheumatic drug as my grandmother at the time illustrates the matter quite well, I think.
40 days [!!!] CBD stays in the blood with LPT technology - that's 26 times [!!!] as long as oral administration! This means that a single subcutaneous injection provided CBD levels for over a month. Now put this in relation to the countless positive reports linking patients to taking CBD, and that's an exciting scenario for numerous conditions that InnoCan Pharma* (NASDAQ:INNO) seems to be researching into!
MY ASSUMPTIONS WHAT THIS MEDICATION COULD BE USED FOR HAVE NOW BEEN CONFIRMED BY PROF. BARENHOLZ CONFIRMED - THE ORIGINAL TEXT OF THE LAST PRESS RELEASE:
Especially epilepsy, where there is already an approved drug based on CBD (GW Pharma - Epidiolex® - Dravet Syndrome), or multiple sclerosis, where patients use CBD almost miraculous effects would be suitable areas of application in my opinion:
INNOCAN PHARMA CORP.*
WKN: A2PSPW CSE: INNO
Cool thing: With an account at Smartbroker, you can trade this share from 0 euros. - Changing brokers often pays off!!
BLUECHIP-POWER
The management and the scientific advisory board of this company are of a higher caliber than you would expect from a penny stock:
Example Prof. Barenholz: This is one of the most successful and probably also most famous scientists in Israel, Prof. Chezy Barenholz, who received the "Israeli Nobel Prize", the so-called EMET Prize, for his work in 2020.
The EMET Prize, known as "Israel's Nobel Prize", which is awarded for outstanding academic and professional achievements that have had far-reaching impact and made a significant contribution to Israeli society, announced its 2020 winners in five categories: Culture and Arts, Exact Sciences, Life Sciences, Social Sciences and Humanities.
The InnoCan Pharma* (NASDAQ: INNO) crew, which could make even many blue-chip companies green with envy, has set the stage for some biotech innovations that could make urgent medical problems highly treatable and maybe even curable.
LPT: WITH INJECTABLE CBD AGAINST CENTRAL NERVOUS SYSTEM DISEASES
InnoCan Pharma* (NASDAQ:GOLF) announced that an animal study in mice demonstrated a prolonged release of cannabidiol ("CBD") into the blood for at least three weeks after administration. This study was conducted by the Hebrew University of Jerusalem, Israel (Link).
The study, led by Dr. Ahuva Cern, senior researcher in the laboratory of Prof. Barenholz, was performed on over 35 mice in laboratories at the Hebrew University of Jerusalem. 21 days after injection, significant amounts of CBD were still found in the blood of mice treated with a single injection of liposomal CBD. In the second animal experiment it was even 50 days.
Cern, Bincovich, Barenholz
These results are significant when comparing oral versus smoking administration of CBD, where CBD was only found in the blood of mice for a period of up to 36 hours after administration.
Approximately 50 million people worldwide suffer from epilepsy, making it one of the most common neurological disorders worldwide. GW Pharma (NASDAQ: GWPH - $3 billion market cap) is the best-known company in the CBD pharmaceutical space and already has an approved drug (Epidyolex®) for Lennox-Gastaut Syndrome and Dravet Syndrome, two difficult-to-treat forms of childhood epilepsy. The drug must be taken twice a day.
CLX: CBD-LOADED EXOSOMES AGAINST COVID-19?
This news brought the company InnoCan Pharma* (NYSE:INNOCAN) into the focus of investors:
InnoCan Pharma Collaborates with Tel Aviv University to Develop a New Revolutionary Approach to Treat the COVID-19 Corona Virus with Exosomes-Loaded CBD
InnoCan Pharma* (WKN: A2PSPW) wants to test a treatment method against Covid-19 together with Tel Aviv University. To do this, exosomes (particles that form during the formation of stem cells) are "loaded" with CBD molecules (from the cannabis plant). Exosomes have the proven ability to find damaged cells in the body and initiate a repair process. Not only does CBD have the property of being anti-inflammatory, it can also (according to the latest research) block the "gate" through which the virus enters a cell. The innovative combination is to be introduced into the lungs attacked by Covid-19 by inhalation and, in the best case, heal them.
There is ample evidence that stem cell or exosome therapy could be the key to fighting Covid-19 disease. A landmark clinical study from Christ Hospitals in Jersey City, New Jersey, USA, has been published entitled "Bone marrow mesenchymal stem cell exosomes for the treatment of severe COVID-19" (https://pubmed.ncbi.nlm).nih.gov /32380908/).
The virus is here to stay. Vaccination will bring relief, but people will still get sick with Covid-19. An effective therapy against the so-called cytokine storm caused by the virus, which can then cause lung failure (also in other infectious lung diseases), is now the top priority of the researchers. The company recently took a huge step forward in InnoCan Pharma's promising research approach to load exosomes with CBD molecules: Innocan Pharma Successfully Completes Large Scale Production of Exosomes
With CBD AGAINST MUSCLE SONERSHIP + CBD BEAUTY PRODUCTS
InnoCan Pharma* (NYSE:InnoCan Pharma*) recently announced that 95% of testers using the Relief & Go OTC Pain Relief Spray Experience Pain Reduction (News).
Pain is the unfortunate rule in competitive sports due to the constant overstraining of joints, tendons and muscles. The patent-pending anti-pain spray tackles the problem from three sides. The combination of three active ingredients, menthol, magnesium and CBD, should make a very effective treatment possible. It should be noted that magnesium is normally only taken orally, but thanks to the patented formula it can go directly through the skin to the area of action.
InnoCan Pharma* (NYSE:InnoCan) also recently reported that its SHIR premium CBD facial serum reduced wrinkles by 90% after four weeks of treatment in a clinical study (News).
CONCLUSION:
If you look at the price development of InnoCan over the last few months, you will see a winning share! I think this should continue to be the case.
You can find the original article HERE!
Helmut Pollinger
*Please note the following information on the conflicts of interest definitely existing at bullVestor with regard to this publication as well as our risk information and our disclaimer
Subscribe to my free newsletter
Risk Notice and Disclaimer
We expressly point out that we assume no liability for the content of external links. Every investment in securities involves risks. Political, economic or other changes can lead to significant price losses. This applies in particular to investments in (foreign) second-line stocks and in small and microcap companies. Due to the low market capitalization, investments in such securities are highly speculative and involve a high risk, up to and including the total loss of the invested capital. In addition, some of the stocks presented at bullVestor are subject to currency risks.
The background information and market assessments published by bullVestor for the German-speaking area were created in compliance with the Austrian and German capital market regulations and are therefore intended exclusively for capital market participants in the Republic of Austria and the Federal Republic of Germany. Other foreign capital market regulations were not taken into account and do not apply in any way. BullVestor's publications are for informational purposes only and expressly do not represent a financial analysis, but are promotional texts of a purely advertising nature for the companies discussed, which pay a fee for this.
By purchasing the bullVestor publications, no consulting contract comes about between the reader and the authors or the publisher. All information and analyzes do not represent an invitation, offer or recommendation to buy or sell investment instruments or for other transactions. Every investment in shares, bonds, options or other financial products is associated with risks, some of which are considerable.
The editors and authors of the bullVestor publications are not professional investment advisors. It is therefore essential that you always seek advice from a qualified specialist (e.g. your house bank or a qualified advisor you trust) when making your investment decisions. All information and data published by bullVestor comes from sources that we believe to be reliable and trustworthy at the time of writing. However, no guarantee can be given with regard to the correctness and completeness of this information and data.
The same applies to the evaluations and statements contained in bullVestor's analyzes and market assessments. These were created with due care. Any responsibility or liability for the correctness and completeness of the information contained in this publication is excluded. All statements of opinion made reflect the current assessment of the authors, which can change at any time without prior notice. There is expressly no guarantee or liability that the price or profit developments forecast in the bullVestor publications will occur.
Conflicts of interest disclosures
The publisher and responsible authors hereby declare that the following conflicts of interest exist with regard to the company discussed in this publication at the time of publication:
Imprint:
bullVestor Medien GmbHGutenhofen 44300 St. Valentin Austria Tel: +43 7435 54077-0 Company registration number: FN275279yManaging director and 100% owner: Helmut PollingerPlace of jurisdiction: St. Pöltenkontakt[at]bullvestor.at- advertisement -
Values included: CA45783P1027
